Cytoplasmic phosphorylated ERK1/2 expression in patients with melanoma is associated with tumor stage and metastasis

References

• Badash I, Shauly O, Lui CG, Gould DJ, Patel KM. 2019. Nonmelanoma facial skin cancer: a review of diagnostic strategies, surgical treatment, and reconstructive techniques. Clin Med Insight Ear Nose Throat. 12:1179550619865278.
   Google Scholar
• Chen RH, Sarnecki C, Blenis J. 1992. Nuclear localization and regulation of ERK- and RSK-encoded protein kinases. Mol Cell Biol. 12:915–927.
   PubMed Web of Science ®Google Scholar
• Chin SY, Wu PR, Shih YH, Yeh CM, Lee WR, Shen SC, Yeh KT, Jiang MC, Tseng JT. 2015. High expression of cytoplasmic phosphorylated CSE1L in malignant melanoma but not in benign nevi: phosphorylated CSE1L for the discrimination between melanoma and benign nevi. Int J Clin Exp Pathol. 8:1393–1401.
   PubMed Web of Science ®Google Scholar
• Crombie IK. 1979. Variation of melanoma incidence with latitude in North America and Europe. Br J Cancer. 40:774–781.
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. 2002. Mutations of the BRAF gene in human cancer. Nature 417:949–954.
   PubMed Web of Science ®Google Scholar
• Davies MA. 2012. The role of the PI3K-AKT pathway in melanoma. Cancer J. 18:142–147.
   PubMed Web of Science ®Google Scholar
• Edge SB, Byrd DR, Compton CC, Fritz AG, Greene F, Trotti A, editors. 2010. Melanoma of the skin. The American joint committee on cancer cancer staging manual. 7thed., Springer Verlag: New York; p. 325–344.
   Google Scholar
• Gogas H, Eggermont AM, Hauschild A, Hersey P, Mohr P, Schadendorf D, Spatz A, Dummer R. 2009. Biomarkers in melanoma. Ann Oncol. 20:vi8–vi13.
   PubMed Web of Science ®Google Scholar
• Ho YJ, Shih CP, Yeh KT, Shi B, Gong Z, Lin YM, Lu JW. 2018. Correlation between high expression levels of jumonji domain-containing 4 and short survival in cases of colon adenocarcinoma. Biochem Biophys Res Commun. 503:1442–1449.
   PubMed Web of Science ®Google Scholar
• Jafari M, Papp T, Kirchner S, Diener U, Henschler D, Burg G, Schiffmann D. 1995. Analysis of ras mutations in human melanocytic lesions: activation of the ras gene seems to be associated with the nodular type of human malignant melanoma. J Cancer Res Clin Oncol. 121:23–30.
   PubMed Web of Science ®Google Scholar
• Jiang MC, Yeh CM, Tai CJ, Chen HC, Lin SH, Su TC, Shen SC, Lee WR, Liao CF, Li LT, Lee CH, Chen YC, Yeh KT, Chang CC. 2013. CSE1L modulates Ras-induced cancer cell invasion: correlation of K-Ras mutation and CSE1L expression in colorectal cancer progression. Am J Surg. 206:418–427.
   PubMed Web of Science ®Google Scholar
• Jovanovic B, Krockel D, Linden D, Nilsson B, Egyhazi S, Hansson J. 2008. Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma. J Invest Dermatol. 128:2696–2704.
   PubMed Web of Science ®Google Scholar
• Kuo HT, Hsu HT, Chang CC, Jiang MC, Yeh CM, Shen KH, Hsu PC, Tai CJ. 2013. High nuclear phosphorylated extracellular signal-regulated kinase expression associated with poor differentiation, larger tumor size, and an advanced stage of breast cancer. Pol J Pathol. 64:163–169.
   PubMed Web of Science ®Google Scholar
• Liao CF, Lin SH, Chen HC, Tai CJ, Chang CC, Li LT, Yeh CM, Yeh KT, Chen YC, Hsu TH, Shen SC, Lee WR, Chiou JF, Luo SF, Jiang MC. 2012. CSE1L, a novel microvesicle membrane protein, mediates Ras-triggered microvesicle generation and metastasis of tumor cells. Mol Med. 18:1269–1280.
   PubMed Web of Science ®Google Scholar
• Lu JW, Lin SH, Yeh CM, Yeh KT, Huang LR, Chen CY, Lin YM. 2020. Cytoplasmic CK1 epsilon protein expression is correlated with distant metastasis and survival in patients with melanoma. In Vivo. 34:2905–2911.
   PubMed Web of Science ®Google Scholar
• Marghoob AA, Koenig K, Bittencourt FV, Kopf AW, Bart RS. 2000. Breslow thickness and clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer Staging. Cancer 88:589–595.
   PubMed Web of Science ®Google Scholar
• Oba J, Nakahara T, Abe T, Hagihara A, Moroi Y, Furue M. 2011. Expression of c-Kit, p-ERK and cyclin D1 in malignant melanoma: an immunohistochemical study and analysis of prognostic value. J Dermatol Sci. 62:116–123.
   PubMed Web of Science ®Google Scholar
• Platz A, Ringborg U, Brahme EM, Lagerlof B. 1994. Melanoma metastases from patients with hereditary cutaneous malignant melanoma contain a high frequency of N-ras activating mutations. Melanoma Res. 4:169–177.
   PubMed Web of Science ®Google Scholar
• Smalley KS. 2003. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer. 104:527–532.
   PubMed Web of Science ®Google Scholar
• Soares C, Melo de Lima Morais T, Carlos R, Mariano FV, Altemani A, Freire de Carvalho MG, Correa MB, Dias Dos Reis RR, Amorim LS, Paes de Almeida O, Jorge J. 2018. Phosphorylated Akt1 expression is associated with poor prognosis in cutaneous, oral and sinonasal melanomas. Oncotarget. 9:37291–37304.
   PubMedGoogle Scholar
• Subramaniam S, Unsicker K. 2006. Extracellular signal-regulated kinase as an inducer of non-apoptotic neuronal death. Neuroscience. 138:1055–1065.
   PubMed Web of Science ®Google Scholar
• Tai CJ, Chang CC, Jiang MC, Yeh CM, Su TC, Wu PR, Chen CJ, Yeh KT, Lin SH, Chen HC. 2012. Clinical-pathological correlation of K-Ras mutation and ERK phosphorylation in colorectal cancer. Pol J Pathol. 63:93–100.
   PubMed Web of Science ®Google Scholar
• Unal EB, Uhlitz F, Bluthgen N. 2017. A compendium of ERK targets. FEBS Lett. 591:2607–2615.
   PubMed Web of Science ®Google Scholar
• Vicent S, Lopez-Picazo JM, Toledo G, Lozano MD, Torre W, Garcia-Corchon C, Quero C, Soria JC, Martin-Algarra S, Manzano RG, Montuenga LM. 2004. ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours. Br J Cancer. 90:1047–1052.
   PubMed Web of Science ®Google Scholar
• Wada T, Penninger JM. 2004. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 23:2838–2849.
   PubMed Web of Science ®Google Scholar
• Widmann C, Gibson S, Jarpe MB, Johnson GL. 1999. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev. 79:143–180.
   PubMed Web of Science ®Google Scholar
• Yajima I, Kumasaka MY, Thang ND, Goto Y, Takeda K, Yamanoshita O, Iida M, Ohgami N, Tamura H, Kawamoto Y, Kato M. 2012. RAS/RAF/MEK/ERK and PI3K/PTEN/AKT signaling in malignant melanoma progression and therapy. Dermatol Res Pract. 2012:354191.
   PubMedGoogle Scholar
• Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Palmer AA, Zhang XD, Thompson JF, Bron LP, Hersey P. 2005. Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma. J Clin Pathol. 58:1163–1169.
   PubMed Web of Science ®Google Scholar